Find policies, billing codes, payers, states, and providers
Bariatric Surgery (for Kentucky Only)
Customize your policy alerts
Sign up for UnitedHealthcare Policy CS007KY.12 alerts
Get alerted when Policy CS007KY.12 changes without checking for updates manually.
Monitor payer policy activity
Medical policy governing bariatric and metabolic surgical procedures for UnitedHealthcare Community Plan members in the state of Kentucky, including coverage rationale, definitions, coding, and documentation requirements.
Silastic ring vertical gastric bypass was added to the list of unproven and not medically necessary procedures.
Transoral endoscopic surgery including transoral outlet reduction (TORe) was added to the list of unproven and not medically necessary procedures.
Stomach aspiration therapy was removed from the list of unproven and not medically necessary procedures.
Gastrointestinal liners wording was replaced with 'transoral endoscopic surgery including gastrointestinal liners'.
Intragastric balloon wording was replaced with 'transoral endoscopic surgery including intragastric balloon'.
Transoral endoscopic surgery language was replaced with 'transoral endoscopic surgery including endoscopic sleeve gastroplasty (includes OverStitch ™ )'.
Applicable CPT codes were updated to reflect annual edits and code 43889 was added.
Coverage Criteria and Policy Determinations
InterQual-based Medical Necessity
Covered when InterQual CP Bariatric or Metabolic Surgery criteria are met
Policy references InterQual for specific clinical criteria and decision logic
Unproven / Not Medically Necessary Procedures
Not medically necessary for treating obesity due to insufficient evidence of efficacy
Items enumerated in policy chunk 4
Described surgical and endoscopic bariatric procedures
Procedures described and clinical considerations
No explicit per-procedure medical necessity decision logic present in these descriptive sections
SADI-S / SADS clinical evidence
Evidence summaries and required considerations for SADI-S/SADS:
Long-term randomized controlled trial evidence lacking; monitor for malabsorption and GERD after hypoabsorptive procedures
Evidence base is primarily observational
Endoscopic bariatric procedures (ESG, transoral endoscopic)
Evidence summaries and considerations for endoscopic bariatric procedures (ESG and transoral endoscopic surgery):
Comparative trials vs surgical procedures and contemporary pharmacotherapy are limited or absent
Policy may treat these procedures cautiously for coverage pending stronger evidence
Gastrointestinal liners (EndoBarrier)
Evidence summaries and considerations for gastrointestinal liners (DJBL/EndoBarrier):
Device considered investigational pending additional high-quality RCTs and long-term data
Intragastric balloons
Evidence summaries and considerations for intragastric balloons (IGBs):
Trial inclusion commonly required prior unsuccessful nonsurgical weight loss and adherence to dietary restrictions; programs must ensure follow-up capacity
Evidence-based coverage considerations (informational)
Evidence and guideline-derived considerations (no explicit payer coverage logic present in these chunks)
ASGE PIVI thresholds met for some devices (Orbera) although long-term benefit remains uncertain
Coverage determinations rely on overall policy clinical criteria and InterQual where applicable
Informational guidance to support prior authorization and documentation expectations
Indications for MBS per major societies
Society guideline indications and selection considerations for bariatric/metabolic surgery
Include ethnicity-based BMI adjustments and consideration for adolescents
Endoscopic therapies (IGB) guidance
Endoscopic bariatric therapies (EBTs) and intragastric balloons
ASGE PIVI thresholds and AGA recommendations inform appropriate use and follow-up
Revisional bariatric surgery
Revisional bariatric surgery considerations
Surgeon experience, anatomy, prior procedure, and patient factors should guide procedure selection
Revisional Bariatric Surgery — General coverage criteria
Covered when patient evaluation and procedure selection meet multidisciplinary assessment and indication criteria
Reoperative procedures carry higher risk and require documentation of multidisciplinary assessment
Distalization-specific criteria
Additional requirement for distalization procedures
Nutritional monitoring and supplementation plans must be documented prior to surgery
Pediatric surgery criteria
Pediatric metabolic/bariatric surgery considerations
Exclude pregnant or breastfeeding adolescents and patients with unresolved substance use, eating disorders, or untreated psychiatric illness
Device-specific FDA indication criteria (informational for coverage determination)
Covered when ALL FDA-labeled selection criteria are met for the specific device (informational; coverage decisions rely on policy-wide clinical criteria elsewhere).
Per LAP-BAND PMA and labeling; adjustable gastric bands contraindicated in patients <18 years
LAP-BAND expanded indication (2011)
Additional FDA-labeled selection criteria after 2011 approval.
Informational; conservative therapy failure per labeling
TransPyloric Shuttle (PMA 2019)
FDA premarket approval indication.
Informational—document device-specific selection criteria when requesting authorization
EndoBarrier
Investigational status.
Device remains investigational per FDA IDE (Aug 2018)
The policy explicitly states that bariatric surgery performed as the primary treatment for any condition other than obesity is unproven and not medically necessary. This listing is part of the policy’s enumerated unproven / not medically necessary procedures and therefore is excluded from favorable coverage absent evidence supporting that indication.
Gastrointestinal liners such as the EndoBarrier™ are described in the policy as not approved by the U.S. Food and Drug Administration for use in the United States and are therefore limited by federal law to investigational use only. The policy groups gastrointestinal liners under transoral endoscopic approaches and treats EndoBarrier as investigational pending additional clinical evidence and regulatory approval.
The policy concludes that bariatric artery embolization remains investigational and unproven because available human studies are small, methodologically limited, use variable techniques, and lack long‑term safety and efficacy data. As such, the procedure is presented as not established and treated as an investigational/non‑covered approach until larger, controlled datasets demonstrate benefit and acceptable risk.
Implantable gastric electrical stimulation is described as having insufficient high‑quality evidence regarding magnitude and durability of effect and an unclear risk profile. The policy therefore characterizes gastric electrical stimulation as investigational, reflecting an implied exclusion from standard coverage pending more robust randomized data and long‑term outcomes.
The policy notes that laparoscopic greater curvature plication (LGCP) provides inferior and less durable weight loss compared with established procedures and carries notable revision and complication rates. Given these comparative limitations and the need for additional high‑quality RCTs, LGCP is listed among unproven interventions and is suggested to be excluded from standard coverage.
Several procedures are identified as having insufficient evidence, higher complication rates, or limited long‑term outcomes. These include LGCP (high revision and weight‑regain concerns), OAGB/MGB (higher rates of de novo GERD and marginal ulcers in pooled analyses), silastic ring vertical gastric bypass (SRVGB) (device‑specific late complications and lack of standardization), and SADI‑S/SADS (promising short‑ to mid‑term weight loss but limited long‑term safety data and risk of malabsorption). The policy treats these techniques cautiously and may restrict or consider them not medically necessary pending stronger evidence.
The policy highlights procedures and devices with mixed or insufficient evidence—examples include transoral endoscopic surgery (including endoscopic sleeve gastroplasty and TORe), certain ingestible intragastric balloons, and duodenal‑jejunal bypass liners (DJBL/EndoBarrier). These interventions are described as requiring additional randomized trials and long‑term outcome data before they can be considered established therapy; until such evidence is available, they are presented as investigational or limited‑evidence options.
The clinical evidence summaries do not list explicit blanket exclusions for some devices but emphasize that available studies show inconclusive long‑term benefit, frequently high loss to follow‑up, and—for some products—lack of regulatory approval. The policy therefore treats such technologies as unproven or investigational and notes that long‑term effectiveness is uncertain unless paired with sustained adjunctive treatments.
Although no explicit exclusion language appears in this excerpt for all intragastric balloon contexts, the policy references ASMBS guidance that emphasizes adherence to contraindications, timely device removal, and careful patient selection to mitigate safety risks. That guidance informs the policy’s cautious stance toward certain balloon uses.
Pediatric considerations are stated clearly: bariatric surgery should not be performed in preadolescent children, and it should be avoided in pregnant or breastfeeding adolescents and those planning pregnancy within two years. Pediatric eligibility requires multidisciplinary assessment and adherence to society guidance on maturity and psychosocial readiness.
The policy lists several relative contraindications that may preclude operative candidacy or require careful evaluation, including severe heart failure, unstable coronary artery disease, end‑stage lung disease, active cancer diagnosis/treatment, cirrhosis with portal hypertension, uncontrolled substance use, and severely impaired intellectual capacity. These conditions warrant individualized risk‑benefit assessment prior to considering bariatric procedures.
Per FDA labeling cited in the policy, adjustable gastric bands are contraindicated in patients younger than 18 years of age. This device‑specific contraindication is noted as a potential basis for noncoverage when applied outside the labeled population.
The policy enumerates specific procedures designated as unproven and not medically necessary; the 08/01/2026 revision explicitly added silastic ring vertical gastric bypass and clarified transoral endoscopic groupings (including TORe). These named interventions are listed as not medically necessary due to insufficient evidence supporting safety and long‑term efficacy.
Interventions listed in the policy’s unproven list—including endovascular, implantable stimulation, various endoscopic and surgical variants, and device therapies—are characterized as not medically necessary for treating obesity when evidence is insufficient. Transoral endoscopic procedures and gastrointestinal liners (e.g., EndoBarrier) are specifically referenced as investigational or not approved, supporting their not‑medically‑necessary designation.
Transoral endoscopic approaches (including endoscopic sleeve gastroplasty, TORe, and other natural‑orifice techniques) and certain gastrointestinal liners are presented as investigational or investigational options in the policy; the EndoBarrier device is specifically noted as not FDA‑approved and limited to investigational use in the U.S.
Because the policy finds that bariatric artery embolization evidence is limited, heterogeneous, and of small size with unclear long‑term outcomes and safety, it is described as unproven; this supports an investigational or not‑medically‑necessary classification until higher‑quality controlled data become available.
Provider Requirements, Prior Authorization, and Documentation
Use InterQual criteria to establish medical necessity
Medical necessity determinations for bariatric and metabolic surgical procedures rely on the referenced InterQual CP criteria for Bariatric or Metabolic Surgery (adult) and Bariatric or Metabolic Surgery (Adolescent).
Prior authorization: document multidisciplinary assessment for revisional surgery
When requesting authorization for revisional bariatric surgery, include documentation that a thorough multidisciplinary assessment was performed and that the revision is indicated (for example, due to anatomical causes, complications, or device issues) rather than solely behavioral factors.
- Document multidisciplinary evaluation findings and rationale for revision
- Describe prior procedure(s), complications, and anatomical findings
- Show consideration of nonoperative management and MBSAQIP center accreditation where applicable
No specific CPT/HCPCS prior-authorization list in this section
This policy excerpt provides clinical evidence and guidance but does not list specific CPT or HCPCS codes that by itself mandate prior authorization; applicable authorization requirements are determined by InterQual and the payer’s administrative rules.
Prior authorization advised for less-proven procedures
For procedures with limited, mixed, or insufficient long-term evidence (for example LGCP, OAGB/MGB, SRVGB, and some SADI-S/SADS reports), prior authorization may be required and should include supporting clinical evidence and justification.
- Provide clinical rationale and available outcome data when seeking coverage
- Include surgeon experience and follow-up plans when evidence is limited
Align prior-authorization info with IGB trial inclusion criteria
When intragastric balloon (IGB) or similar device use is proposed based on trial populations, prior authorization should reflect trial-like inclusion elements: adult age, BMI ≥ 30 kg/m2, prior unsuccessful nonsurgical weight-loss attempts, and willingness to adhere to required dietary restrictions and follow-up.
- Confirm patient age and BMI meet study-referenced thresholds
- Document history of failed conservative weight-loss efforts
- Document patient agreement to required dietary program and follow-up schedule
Authorization must confirm trial-like eligibility elements
Prior authorization review should verify that the patient meets the study-type eligibility elements commonly used in IGB and device trials (for example BMI thresholds and documented prior failure of conservative therapy) before approving device-based interventions.
- Verify BMI and comorbidity criteria documented in the record
- Confirm documented prior conservative therapy attempts and their duration
- Include planned multidisciplinary follow-up in the authorization request
IGB: limit duration and ensure removal/follow-up capability
Intragastric balloons are temporary devices; follow FDA and ASMBS guidance limiting implantation to a maximum of 6 months and ensure programs can provide timely removal and appropriate follow-up to mitigate device-related complications.
- Document plan for device removal within the 6-month maximum
- Document ability to provide nutrition follow-up and complication management
Prior authorization must document indications and prior-procedure details for revisional surgery
Prior authorization for revisional surgery should include evidence of multidisciplinary evaluation, the specific indication for revision (insufficient weight loss, persistent comorbidity, or complication), and details of the prior procedure and outcomes.
- Provide prior operative reports and documentation of prior outcomes
- Describe the multidisciplinary team's assessment and recommended plan
- Detail anticipated benefits and the management plan for increased reoperative risks
Document FDA-indicated selection criteria for device requests
When seeking authorization for device-based therapies, document that the patient meets FDA-labeled selection criteria for the specific device (for example LAP-BAND and TransPyloric Shuttle BMI and comorbidity thresholds) as applicable.
- Include device name and FDA-indicated BMI/comorbidity criteria in the record
- Document prior failure of supervised conservative therapies when required by labeling
Authorization requests: follow InterQual and include updated CPT codes
Prior authorization and utilization review may be required per InterQual and UnitedHealthcare medical policy criteria; the policy’s applicable CPT code list was updated and includes added code 43889.
- Use InterQual decision support for clinical criteria during authorization
- When submitting, include applicable CPT codes (note 43889 added in update)
Confirm first-line conservative treatments attempted
First-line obesity treatments (dietary therapy, physical activity, behavior modification, and medication management) are expected to have been attempted prior to consideration of procedural interventions.
Record failed conservative therapy prior to procedural consideration
Document attempts at conservative obesity treatment—diet, physical activity, behavior modification, and medication management—before proceeding to invasive procedures when indicated by societal guidance.
- Record duration and type of supervised programs or pharmacotherapy trials
- Include documentation of outcomes and adherence
No explicit step-therapy requirements specified here
No explicit step-therapy program requiring sequential trials is described in this excerpt; device and interventional approaches are assessed against evidence and may be considered investigational or unproven.
Prefer established procedures before less-proven alternatives
Providers and reviewers should favor established procedures (e.g., LSG, RYGB) over less-proven alternatives when comparative data show inferior or less durable outcomes or higher complication rates for the alternative (for example LGCP vs LSG).
- Provide comparative outcome data if proposing less-proven procedures
- Explain why standard procedures are not appropriate in the individual case
Require documented conservative management before ESG
Endoscopic sleeve gastroplasty (ESG) is typically considered only after documentation of unsuccessful conservative management; authorization should include evidence of prior lifestyle interventions.
- Document prior supervised diet/exercise programs and their results
- Include plan for concurrent multidisciplinary follow-up after ESG
Follow guideline-based sequencing versus device-first approaches
Consider metabolic surgery or intensification of medical therapy for diabetes per ADA guidance (including BMI and comorbidity thresholds) before device-only interventions when clinically appropriate; document guideline-based sequencing in the record.
- Document consideration of ADA-recommended options and rationale for chosen therapy
- Include specialist weight-management assessment when indicated
Document multidisciplinary care prior to device therapy
Before device therapy, include evidence of a multidisciplinary approach—nutrition, behavioral health, and surgical assessment—and plans for supervised lifestyle intervention alongside the device.
- Document team members involved and their recommendations
- Provide plan for post-procedure lifestyle support and monitoring
Maintain complete, legible medical-record documentation for reviews
Ensure medical records contain legible documentation that fully supports medical necessity, including relevant history, physical exam, diagnostic test results, and prior weight-loss attempts; records must be available upon request.
- Include past weight history, prior interventions, and objective measures (BMI, labs)
- Maintain legible, retrievable records for utilization review
Adolescent and revisional-case documentation requirements
For adolescents, document use of gender-specific CDC growth and BMI charts to support assessments of development and maturation; for revisional cases, include prior procedure details and outcomes in the record.
- Attach CDC growth/BMI charts and note Tanner stage or maturity where applicable
- Include prior operative reports and reason for considering revision
Supportive documentation required for SADI-S/SADS submissions
When submitting requests for SADI-S/SADS or similar hypoabsorptive procedures, include documentation of indication (BMI, comorbidities), prior procedures if revisional, and surgical technique standardization and follow-up plans.
- Provide BMI and comorbidity data, prior operative details, and planned nutrition monitoring
- Document surgeon experience and technique standardization where possible
Document prior failed nonsurgical weight loss and planned adherence for IGBs
Trials of intragastric balloons required documented prior failure of nonsurgical weight-loss attempts and adherence to dietary restrictions with close follow-up; authorization for IGBs should include similar documentation.
- Document prior nonsurgical weight-loss attempts and outcomes
- Confirm patient willingness to adhere to dietary restrictions and scheduled follow-up
Document prior unsuccessful nonsurgical methods and follow-up agreement
Providers should document prior unsuccessful nonsurgical weight-loss methods and patient willingness to comply with required dietary restrictions and follow-up, as many device trials required these elements for inclusion.
- List prior programs, duration, and results
- Include signed patient agreement to follow-up regimen when available
Document comprehensive preoperative evaluation
Perform and document a comprehensive preoperative evaluation including an obesity-focused history, weight history, comorbidities, prior weight-loss attempts, and results of pertinent laboratory and diagnostic testing.
- Record weight trajectory, comorbidity status, and relevant labs
- Include psychosocial and behavioral health assessments as appropriate
Expect multidisciplinary and pediatric-specific documentation
Thorough multidisciplinary evaluation documentation is expected for patients considered for reoperative or primary metabolic/bariatric surgery; for pediatric candidates, document family psychosocial assessment, puberty status, and evidence of prior lifestyle modification.
- Include team assessments (nutrition, behavioral health, surgery) and family support evaluation for adolescents
- Document Tanner stage or near-final height and access to pediatric bariatric expertise
Include device identification and FDA approval details in documentation
Identify devices in the record using FDA product codes or approval documents (for example OverStitch, TransPyloric Shuttle) when applicable to support device-specific claims.
- List device model and reference FDA approval or product code when applicable
Risk of denial if documentation is insufficient or unavailable
Medical records that do not fully support medical necessity or are unavailable upon request may trigger denial; ensure records comprehensively justify the requested service.
- Provide legible records with relevant history, exam findings, and diagnostic results
- Be prepared to supply records promptly for utilization review
Denial risk: inadequate documentation for revisional surgery
Failure to document a thorough multidisciplinary assessment and explicit consideration of risks and benefits for revisional bariatric surgery may result in denial of coverage.
- Document why revision is anatomically or medically indicated versus behavioral
- Provide evidence of MBSAQIP accreditation or equivalent program resources when available
Denial risk: insufficient evidence or higher complication profiles
Procedures with limited long-term evidence or evidence of higher complication rates (for example OAGB with higher de novo GERD, SRVGB device-specific late risks, or procedures lacking long-term durability) may be denied or require additional justification.
- Provide long-term outcome data and risk mitigation plans when available
- Explain rationale for choosing a higher-risk procedure over established options
Denial risk: limited evidence for some endoscopic procedures
Procedures lacking adequate evidence of safety and efficacy (for example transoral endoscopic surgery and some GI liners) have uncertain benefit and may be at higher risk of denial absent strong supporting documentation.
- Include robust clinical data or trial enrollment information if proposing these procedures
- Indicate participation in research protocols or specialized governance when applicable
Denial risk: evidence limitations for long-term device benefit
Lack of long-term safety or durability data and high loss-to-follow-up rates in studies of devices intended for durable benefit (such as some IGBs and liners) may support a medical necessity denial unless plans for long-term adjunctive treatment and follow-up are documented.
- Document planned long-term treatment strategy (pharmacotherapy, repeat interventions, or surgery) after device removal
- Provide follow-up plan to address expected weight regain risks
Do not deny solely for lack of preoperative weight loss program
There is no high-level evidence to mandate preoperative supervised weight loss; therefore, denial based solely on absence of documented preoperative weight loss programs is not supported by ASMBS guidance and may risk inappropriate denial.
Document selection and nutrition plans for distalization/reoperation
Due to higher morbidity with reoperative bariatric surgery and the nutritional risks after distalization when common channel length is < 200 cm or total alimentary limb length is < 400 cm, document careful patient selection and plans for aggressive nutrition monitoring and supplementation.
- Specify anticipated limb lengths and monitoring/supplementation protocols when distalization is planned
- Document informed consent discussing malnutrition risks
Contraindication: adjustable gastric bands in patients <18 years
Adjustable gastric bands are contraindicated in patients younger than 18 years of age; use outside FDA indications may risk noncoverage or denial.
- Do not request banding procedures for patients under 18 without explicit rationale and applicable exceptions
- Document FDA-indicated criteria when proposing banding in adults
Applicable Codes, Device Indications, and Key Numeric Thresholds
| 0813T | Esophagogastroduodenoscopy, flexible, transoral, with volume adjustment of intragastric bariatric balloon. |
| 43290 | Esophagogastroduodenoscopy, flexible, transoral; with deployment of intragastric bariatric balloon. |
| 43291 | Esophagogastroduodenoscopy, flexible, transoral; with removal of intragastric bariatric balloon(s). |
| 43644 | Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and Roux-en-Y gastroenterostomy (roux limb 150 cm or less). |
| 43645 | Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and small intestine reconstruction to limit absorption. |
| 43647 | Laparoscopy, surgical; implantation or replacement of gastric neurostimulator electrodes, antrum. |
| 43648 | Laparoscopy, surgical; revision or removal of gastric neurostimulator electrodes, antrum. |
| 43659 | Unlisted laparoscopy procedure, stomach. |
| 43770 | Laparoscopy, surgical, gastric restrictive procedure; placement of adjustable gastric restrictive device (e.g., gastric band and subcutaneous port components). |
| 43771 | Laparoscopy, surgical, gastric restrictive procedure; revision of adjustable gastric restrictive device component only. |
| No codes listed |
| GDW | Product code for certain surgical stapling devices (as listed) |
| GAG | Product code for certain surgical stapling devices (as listed) |
| 43889 | CPT code added (description as per annual edits) |
Operational Notes and Evidence Context for Providers
The policy cites an ECRI assessment indicating that the Orbera intragastric balloon yields short‑term weight loss but that most individuals regain much of the lost weight within 6–12 months after removal unless followed by effective long‑term treatments. The absence of durable long‑term benefit is highlighted as a limitation for establishing routine coverage.
The policy references ASMBS guidance noting that there is no randomized controlled trial, large prospective study, or meta‑analysis to support mandated preoperative supervised weight loss. Therefore, denying coverage solely because a patient did not complete a preoperative supervised weight loss program is not supported by that society guidance.
The policy positions endoscopic sleeve gastroplasty (ESG) as a therapy that has demonstrated greater short‑term weight loss than lifestyle modification but less weight loss than laparoscopic sleeve gastrectomy. Consistent with evidence and guideline recommendations, ESG is framed to follow documentation of failed conservative measures and be delivered within a program capable of long‑term follow‑up.
Society guidance cited in the policy (for example ADA recommendations) informs sequencing decisions: consider metabolic surgery or intensification of medical therapy for diabetes per ADA before device‑based interventions when appropriate. Device therapies should be considered in the context of guideline‑recommended care and individualized patient factors.
Definitions and Procedure Descriptions
Policy Revision History and Material Changes
Revised list of unproven and not medically necessary procedures: added silastic ring vertical gastric bypass and transoral endoscopic surgery including transoral outlet reduction (TORe); removed stomach aspiration therapy; broadened terminology to group gastrointestinal liners and intragastric balloons under transoral endoscopic surgery and clarified inclusion of endoscopic sleeve gastroplasty (includes OverStitch ™).
Updated medical records documentation language clarifying that benefit coverage is determined by federal, state, or contractual requirements; expanded requirements that records fully support medical necessity and be made available upon request.
Applicable CPT codes updated to reflect annual edits and CPT code 43889 was added to the list of applicable codes.
Supporting Information sections (Description of Services, Clinical Evidence, FDA, References) were updated to reflect current information and the previous policy version CS007KY.11 was archived.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.